Loading patent…
AssigneesWashington University, Quark Pharmaceuticals, Inc.
InventorsAndrew E. Gelman, Elena Feinstein, Svetlana Adamsky, Igor Mett, Hagar Kalinski, Sharon Avkin-Nachum
Estimating the term…
Disclosed herein are therapeutic methods for treating lung diseases, disorders and injury in a mammal, including treatment of acute respiratory distress syndrome (ARDS), acute lung injury, pulmonary fibrosis (idiopathic), bleomycin induced pulmonary fibrosis, mechanical ventilator induced lung injury, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiolitis obliterans after lung transplantation and lung transplantation-induced acute graft dysfunction, including treatment, prevention or prevention of progression of primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, bronchiolitis obliterans after lung transplantation and/or primary graft dysfunction (PGD) after organ transplantation, in particular in lung transplantation, comprising downregulating the TLR2 gene or both the TLR2 gene and TLR4 gene. Provided herein are compositions, methods and kits for treating lung diseases, disorders and injury.
1-54. (canceled)
A method for treating a lung disorder, lung disease or lung injury in a subject in need thereof comprising administering to the subject a therapeutically-effective combination of at least one TLR2 inhibitor or a pharmaceutically acceptable salt or prodrug thereof, and at least one TLR4 inhibitor or a pharmaceutically acceptable salt or prodrug thereof, thereby treating the lung disorder, lung disease or lung injury in the subject.
60-74. (canceled)
(canceled)
(canceled)
81-90. (canceled)
92-96. (canceled)
A composition comprising at least one TLR2 inhibitor or a pharmaceutically acceptable salt or prodrug thereof and at least one TLR4 inhibitor or a pharmaceutically acceptable salt or prodrug thereof;
(canceled)
(canceled)
104-136. (canceled)
A method for treating a lung disorder, lung disease or lung injury in a subject in need thereof, comprising administering to the subject a therapeutically-effective amount of at least one TLR2 inhibitor or a pharmaceutically acceptable salt or prodrug thereof, thereby treating the lung disorder, lung disease or lung injury in the subject.
141-169. (canceled)
Dependencies are inferred from the claim text.